Expansion strategies for Vδ2 γδT cells in cancer immunotherapy: Activation, cytokines, and culture conditions

doi:10.5306/wjco.v16.i10.110466

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (104)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=44

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=49

Oct 24, 2025 (publication date) through Oct 27, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Oct 24, 2025; 16(10): 110466
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110466

Open in New Tab Full Size Figure Download Figure

Figure 1 Mevalonate pathway. N-aminobisphosphonates, including zoledronate, inhibit the mevalonate pathway by blocking farnesyl pyrophosphate synthase. This results in intracellular accumulation of isopentenyl pyrophosphate and its metabolites, which are recognized by Vδ2 T cells. APC: Antigen-presenting cell; FFPS: Farnesyl pyrophosphate synthase; HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A; HMGCR: 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; IPP: Isopentenyl pyrophosphate.

Citation: Lehman N, Zarobkiewicz M. Expansion strategies for Vδ2 γδT cells in cancer immunotherapy: Activation, cytokines, and culture conditions. World J Clin Oncol 2025; 16(10): 110466
URL: https://www.wjgnet.com/2218-4333/full/v16/i10/110466.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i10.110466